The final analysis discusses the FDA's decision not to exempt small entities from the rule because an exemption for small retailers would shift underage sales to those locations, lessening or eliminating the effectiveness and benefits of the access restrictions.
The analysis showed the FDA thought that overlooking small entities was morally wrong.